Bharati, Sanjay (2022) Exploring new drug targets for type 2 diabetes: Success, challenges and opportunities. Biomedicines, 10 (2). pp. 2-18. ISSN 2227-9059
![]() |
PDF
RMS - 00014691.pdf - Published Version Restricted to Registered users only Download (1MB) | Request a copy |
Abstract
There are substantial shortcomings in the drugs currently available for treatment of type 2 diabetes mellitus. The global diabetic crisis has not abated despite the introduction of new types of drugs and targets. Persistent unaddressed patient needs remain a significant factor in the quest for new leads in routine studies. Drug discovery methods in this area have followed developments in the market, contributing to a recent rise in the number of molecules. Nevertheless, troubling developments and fresh challenges are still evident. Recently, metformin, the most widely used first-line drug for diabetes, was found to contain a carcinogenic contaminant known as N-nitroso dimethylamine (NDMA). Therefore, purity and toxicity are also a big challenge for drug discovery and development. Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Furthermore, researchers must study the importance of mechanistic characteristics of novel compounds, as well as exposure-related hazardous aspects of current and newly identified protein targets, in order to identify new pharmacological molecules with improved selectivity and specificity.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Type 2 diabetes; diabetes mellitus; drug development; drug discovery; lead molecules; new targets. |
Subjects: | Allied Health > MCOAHS Manipal > Nuclear Medicine |
Depositing User: | KMC Library |
Date Deposited: | 18 Jul 2022 04:03 |
Last Modified: | 18 Jul 2022 04:03 |
URI: | http://eprints.manipal.edu/id/eprint/158852 |
Actions (login required)
![]() |
View Item |